{
    "clinical_study": {
        "@rank": "139375", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (trebananib monotherapy)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity."
            }, 
            {
                "arm_group_label": "Arm II (trebananib and anti-VEGF therapy)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive trebananib as in Arm I and either bevacizumab IV over 30-90 minutes on days 1, 15, and 29; pazopanib hydrochloride PO QD on days 1-42; sorafenib tosylate PO BID on days 1-42; or sunitinib malate PO QD on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase II trial studies how well trebananib with or without bevacizumab,\n      pazopanib hydrochloride, sorafenib tosylate, or sunitinib malate works in treating patients\n      with advanced kidney cancer. Trebananib may stop the growth of tumor cells by blocking blood\n      flow to the tumor. Bevacizumab, pazopanib hydrochloride, sorafenib tosylate, and sunitinib\n      malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell\n      growth or by blocking blood flow to the tumor. It is not yet known whether giving trebananib\n      with or without bevacizumab, pazopanib hydrochloride, sorafenib tosylate, or sunitinib\n      malate is more effective in treating kidney cancer."
        }, 
        "brief_title": "Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer", 
        "condition": [
            "Recurrent Renal Cell Cancer", 
            "Stage III Renal Cell Cancer", 
            "Stage IV Renal Cell Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Carcinoma, Renal Cell"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To evaluate the overall response rate (complete response [CR] + partial response [PR]) of\n      AMG 386 (trebananib) alone and in combination with continuation of previously administered\n      bevacizumab, pazopanib (pazopanib hydrochloride), sorafenib (sorafenib tosylate), or\n      sunitinib (sunitinib malate) in advanced renal cell carcinoma.\n\n      SECONDARY OBJECTIVES:\n\n      I. To evaluate progression free survival in each arm. II. To evaluate the tolerance and\n      toxicity of AMG 386 alone and in combination with continuation of the prior vascular\n      endothelial growth factor (VEGF) targeted agent.\n\n      TERTIARY OBJECTIVES:\n\n      I. To evaluate the association between pretreatment tumor gene expression levels and\n      response to AMG 386 in combination with continuation of the prior VEGF targeted agent.\n\n      II. To evaluate the association between single nucleotide polymorphisms (SNPs) in angiogenic\n      genes and response to AMG 386 in combination with continuation of the prior VEGF targeted\n      agent.\n\n      III. To compare changes in circulating angiogenic factors in patients treated with AMG 386\n      monotherapy to those treated with AMG 386 in combination with VEGF-targeted therapy.\n\n      IV. To compare expression of angiogenic genes from archival tumor specimens to the\n      expression in biopsy specimens obtained after progression on anti-VEGF therapy.\n\n      OUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\n      ARM I: Patients receive trebananib intravenously (IV) over 30-60 minutes on days 1, 8, 15,\n      22, 29, and 36. Courses repeat every 42 days in the absence of disease progression or\n      unacceptable toxicity.\n\n      ARM II: Patients receive trebananib as in Arm I and either bevacizumab IV over 30-90 minutes\n      on days 1, 15, and 29; pazopanib hydrochloride orally (PO) once daily (QD) on days 1-42;\n      sorafenib tosylate PO twice daily (BID) on days 1-42; or sunitinib malate PO QD on days\n      1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable\n      toxicity.\n\n      After completion of study treatment, patients are followed up for 4-8 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically or cytologically confirmed renal cell carcinoma\n             except medullary or collecting duct subtypes; sarcomatoid differentiation will be\n             allowed\n\n          -  Patients must have measurable disease, defined as at least one lesion that can be\n             accurately measured in at least one dimension (longest diameter to be recorded for\n             non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional\n             techniques or as >= 10 mm with spiral computed tomography (CT) scan, magnetic\n             resonance imaging (MRI), or calipers by clinical exam\n\n          -  Patients must have documented radiologic or clinical progressive disease following at\n             least one prior anti-VEGF regimen administered either as a single agent or in\n             combination with other agents for at least 8 weeks; the prior anti-VEGF treatment\n             regimen must have included bevacizumab, pazopanib, sorafenib or sunitinib\n             administered not more than 12 weeks before study entry; Note: enrollment not more\n             than 8 weeks after the last dose of anti-VEGF therapy is encouraged; nevertheless,\n             intercurrent therapy with an mammalian target of rapamycin (mTOR) inhibitor\n             (everolimus or temsirolimus) will be allowed if progression on that treatment is\n             observed within 12 weeks of the prior anti-VEGF therapy\n\n          -  Any number of prior regimens is allowed; prior investigational therapy is allowed\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)\n\n          -  Life expectancy of greater than 3 months\n\n          -  Leukocytes >= 3,000/mcL\n\n          -  Absolute neutrophil count >= 1,500/mcL\n\n          -  Platelets >= 100,000/mcL\n\n          -  Total bilirubin within normal institutional limits\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])\n             =< 2.5 X institutional upper limit of normal\n\n          -  Partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) =<\n             upper limit of normal (ULN) per institutional laboratory range\n\n          -  International normalized ratio (INR) =< 1.5\n\n          -  Creatinine within normal institutional limits OR creatinine clearance > 40 mL/min per\n             24 h urine collection or calculated according to the Cockcroft-Gault formula\n\n          -  Urinary protein =< 100 mg/dL in urinalysis or =< 1+ on dipstick, unless quantitative\n             protein is < 1000 mg in a 24 h urine sample\n\n          -  Generally well-controlled blood pressure with systolic blood pressure =< 140 mmHg AND\n             diastolic blood pressure =< 90 mmHg prior to enrollment; the use of anti-hypertensive\n             medications to control hypertension is permitted\n\n          -  Patients must have a tumor site amenable to biopsy as determined by the treating\n             investigator; any questions regarding suitability of a site for biopsy will be\n             adjudicated by the principal investigator\n\n          -  Patients must be willing to consent to tumor biopsy for research purposes\n\n          -  Patients should have archival tumor tissue (either unstained slides or tumor blocks)\n             available for retrieval\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control; abstinence) prior to study entry, for\n             the duration of study participation, and 6 months after completion of AMG 386; should\n             a woman become pregnant or suspect she is pregnant while she or her partner is\n             participating in this study, she should inform her treating physician immediately;\n             men treated or enrolled on this protocol must also agree to use adequate\n             contraception prior to the study, for the duration of study participation, and 6\n             months after completion of AMG 386 and bevacizumab, pazopanib, sunitinib, or\n             sorafenib administration\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Intolerance of prior treatment with bevacizumab, pazopanib, sorafenib, or sunitinib;\n             Note: subjects who required a dose reduction of pazopanib, sorafenib, or sunitinib\n             during prior therapy MAY be eligible if they tolerated the agent after dose level\n             reduction (to a minimum of dose level -2 as defined in this protocol)\n\n          -  Central nervous system metastases unless: (1) metastases have been treated and have\n             remained controlled for at least two weeks following treatment, AND (2) patient has\n             no residual neurological dysfunction off corticosteroids for at least one week; a CT\n             or MRI to evaluate for central nervous system (CNS) disease is required for\n             symptomatic patients only\n\n          -  History of venous or arterial thromboembolism within 12 months prior to\n             enrollment/randomization\n\n          -  History of clinically significant bleeding within 6 months of\n             enrollment/randomization\n\n          -  Unresolved toxicities from prior systemic therapy that are Common Terminology\n             Criteria in Adverse Events (CTCAE) version 3.0 or 4.0 >= grade 2 in severity except\n             alopecia\n\n          -  Currently or previously treated with AMG 386, or other molecules that inhibit the\n             angiopoietins or Tie2 receptor\n\n          -  Clinically significant cardiovascular disease within 12 months prior to\n             enrollment/randomization, including myocardial infarction, unstable angina, grade 2\n             or greater peripheral vascular disease, cerebrovascular accident, transient ischemic\n             attack, congestive heart failure, or arrhythmias not controlled by outpatient\n             medication or placement of percutaneous transluminal coronary angioplasty/stent\n\n          -  Major surgery within 28 days prior to enrollment or still recovering from prior\n             surgery\n\n          -  Minor surgical procedures except placement of tunneled central venous access device\n             within 3 days prior to enrollment\n\n          -  Non-healing wound, ulcer (including gastrointestinal), or fracture\n\n          -  Subject not consenting to the use of highly effective contraceptive precautions\n             (e.g., double barrier method [i.e., condom plus diaphragm]) during the course of the\n             study and for 6 months after administration of the last study medication\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to AMG 386 or the anti-VEGF agent used in study\n\n          -  History of allergic reactions to bacterially-produced proteins\n\n          -  Patients who have had anti-VEGFR tyrosine kinase inhibitor within 1 week, mTOR\n             inhibitor within 1 week or anti-VEGF antibody therapy within 3 weeks prior to\n             entering the study; patients who have had other forms of chemotherapy or radiotherapy\n             within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study\n             or those who have not recovered from adverse events due to agents administered more\n             than 4 weeks earlier\n\n          -  Patients who have not yet completed at least 21 days (30 days for prior monoclonal\n             antibody therapy) since ending other investigational device or drug trials, or who\n             are currently receiving other investigational treatments\n\n          -  Patients receiving any medications or substances that are strong inhibitors or\n             inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP450 3A4) are\n             ineligible; caution is advised for patients requiring weak or moderate CYP450 3A4\n             inhibitors or inducers; specifically prohibited medicines include indinavir,\n             nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone,\n             carbamazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St.\n             John's wort, and troglitazone\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Pregnant women are excluded from this study; breastfeeding must be discontinued if\n             the mother is treated with AMG 386\n\n          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral\n             therapy are ineligible; appropriate studies will be undertaken in patients receiving\n             combination antiretroviral therapy when indicated\n\n          -  Inability to take oral medications on a continuous basis; patients who are to take\n             pazopanib, sorafenib, or sunitinib and are unable to swallow pills whole are\n             ineligible (the pills cannot be crushed or broken)\n\n          -  Any condition which in the investigator's opinion makes the subject unsuitable for\n             study participation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "78", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01664182", 
            "org_study_id": "NCI-2012-01289", 
            "secondary_id": [
                "NCI-2012-01289", 
                "CDR0000738785", 
                "PHII-122", 
                "9048", 
                "N01CM00038", 
                "P30CA033572"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm I (trebananib monotherapy)", 
                    "Arm II (trebananib and anti-VEGF therapy)"
                ], 
                "description": "Given IV", 
                "intervention_name": "trebananib", 
                "intervention_type": "Biological", 
                "other_name": [
                    "AMG 386", 
                    "AMG386"
                ]
            }, 
            {
                "arm_group_label": "Arm II (trebananib and anti-VEGF therapy)", 
                "description": "Given IV", 
                "intervention_name": "bevacizumab", 
                "intervention_type": "Biological", 
                "other_name": [
                    "anti-VEGF humanized monoclonal antibody", 
                    "anti-VEGF monoclonal antibody", 
                    "Avastin", 
                    "rhuMAb VEGF"
                ]
            }, 
            {
                "arm_group_label": "Arm II (trebananib and anti-VEGF therapy)", 
                "description": "Given PO", 
                "intervention_name": "pazopanib hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GW786034B", 
                    "Votrient"
                ]
            }, 
            {
                "arm_group_label": "Arm II (trebananib and anti-VEGF therapy)", 
                "description": "Given PO", 
                "intervention_name": "sorafenib tosylate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BAY 43-9006", 
                    "BAY 43-9006 Tosylate Salt", 
                    "BAY 54-9085", 
                    "Nexavar", 
                    "SFN"
                ]
            }, 
            {
                "arm_group_label": "Arm II (trebananib and anti-VEGF therapy)", 
                "description": "Given PO", 
                "intervention_name": "sunitinib malate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "SU11248", 
                    "sunitinib", 
                    "Sutent"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (trebananib monotherapy)", 
                    "Arm II (trebananib and anti-VEGF therapy)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Arm I (trebananib monotherapy)", 
                    "Arm II (trebananib and anti-VEGF therapy)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Monoclonal", 
                "Endothelial Growth Factors", 
                "Bevacizumab", 
                "Sunitinib", 
                "Sorafenib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "contact": {
                    "email": "ptwardowski@coh.org", 
                    "last_name": "Przemyslaw W. Twardowski", 
                    "phone": "626-256-4673ext62307"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }, 
                "investigator": {
                    "last_name": "Przemyslaw W. Twardowski", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "diquinn@usc.edu", 
                    "last_name": "David I. Quinn", 
                    "phone": "323-865-3956"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "University of Southern California/Norris Cancer Center"
                }, 
                "investigator": {
                    "last_name": "David I. Quinn", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "thomas.semrad@ucdmc.ucdavis.edu", 
                    "last_name": "Thomas J. Semrad", 
                    "phone": "916-734-3771"
                }, 
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "University of California at Davis Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Thomas J. Semrad", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "skoehler@cohmg.com", 
                    "last_name": "Stephen C. Koehler", 
                    "phone": "626-396-2900"
                }, 
                "facility": {
                    "address": {
                        "city": "South Pasadena", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91030"
                    }, 
                    "name": "City of Hope South Pasadena"
                }, 
                "investigator": {
                    "last_name": "Stephen C. Koehler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "vaishamu@karmanos.org", 
                    "last_name": "Ulka N. Vaishampayan", 
                    "phone": "313-576-8715"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Wayne State University/Karmanos Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Ulka N. Vaishampayan", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cbelani@psu.edu", 
                    "last_name": "Chandra P. Belani", 
                    "phone": "717-531-1078"
                }, 
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17033-0850"
                    }, 
                    "name": "Penn State Milton S Hershey Medical Center"
                }, 
                "investigator": {
                    "last_name": "Chandra P. Belani", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "applemanlj@upmc.edu", 
                    "last_name": "Leonard J. Appleman", 
                    "phone": "412-648-6507"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15232"
                    }, 
                    "name": "University of Pittsburgh Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Leonard J. Appleman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase 2 Study of AMG 386 With or Without Continued Anti-vascular Endothelial Growth Factor (VEGF) Therapy in Patients With Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib", 
        "other_outcome": [
            {
                "measure": "Pre-treatment tumor gene expression levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "SNPs in angiogenic genes", 
                "safety_issue": "No", 
                "time_frame": "Up to 8 weeks"
            }, 
            {
                "description": "Analyzed as continuous variables (most likely after transformation). The gene expression results from the pretreatment tumor biopsies are expressed as ratios between that of the gene of interest and the internal reference gene beta-actin and can be analyzed as continuous variables - generally after log transformation.", 
                "measure": "Changes in circulating angiogenic factors", 
                "safety_issue": "No", 
                "time_frame": "Baseline to up to 8 weeks"
            }, 
            {
                "measure": "Expression of angiogenic genes in RCC tumors", 
                "safety_issue": "No", 
                "time_frame": "Up to 8 weeks"
            }
        ], 
        "overall_official": {
            "affiliation": "Beckman Research Institute", 
            "last_name": "Thomas Semrad", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall tumor response rate defined as the total number of efficacy-evaluable patients who achieve a complete or partial response by Response Evaluation Criteria in Solid Tumors version 1.1 criteria", 
            "safety_issue": "No", 
            "time_frame": "Up to 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01664182"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Kaplan-Meier plots will be used to display the PFS in each arm.", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "From start of treatment to time of progression or death, whichever occurs first, assessed up to 8 weeks"
            }, 
            {
                "measure": "Tolerance of trebananib alone and in combination with anti-VEGF agent assessed using Common Terminology Criteria for Adverse Events version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8 weeks"
            }, 
            {
                "description": "Toxicities (grade, type, cycle, and attribution) experienced will be listed for each patient and summarized using standard descriptive methods, such as point estimates and associated confidence intervals.", 
                "measure": "Toxicity of trebananib alone and in combination with anti-VEGF agent assessed using Common Terminology Criteria for Adverse Events version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8 weeks"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}